Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | FASN | P49327 | 1/20 | 1.00 |
| ▸ | KAT2A | Q92830 | 3/20 | 0.77 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360509 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL7920321 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL7920753 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| Protolichesterinic Acid SCHEMBL7913878 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL13193435 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL7920757 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL3007085 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL6428922 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL7913818 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL6428925 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202795-B2 | Means and methods for treatment of early-onset Parkinson's disease | VIB VZW (BE) | 2021-12-21 | — | — | US | disclosed |
| US-20170319610-A1 | MEANS AND METHODS FOR TREATMENT OF EARLY-ONSET PARKINSON'S DISEASE | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-11-09 | — | — | US | disclosed |
| EP-2766349-B1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF | SANOFI SA (FR) | 2016-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319610-A1 | MEANS AND METHODS FOR TREATMENT OF EARLY-ONSET PARKINSON'S DISEASE | PINK1, PARK7, SNCA | POLB 384/4885FASN 143/4885KAT2A 1574/4885 |
| US-11202795-B2 | Means and methods for treatment of early-onset Parkinson's disease | PINK1, PARK7, SNCA | POLB 384/4885FASN 143/4885KAT2A 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.